论文部分内容阅读
新辅助化疗是指在局部治疗(手术或放疗)前给予的全身化疗。近年来,宫颈癌的新辅助化疗日益受到人们的关注,新辅助化疗可减少肿块体积,消除亚临床转移,以期延长患者的生存期。许多研究表明,癌细胞内在的抗原成分、基因、蛋白与化疗的敏感性相关,可以通过检测患者体内的相关标志物在新辅助化疗前后变化来判断患者的疗效,为宫颈癌患者作出综合治疗方案提供依据。
Neoadjuvant chemotherapy refers to systemic chemotherapy given prior to topical treatment (surgery or radiotherapy). In recent years, neoadjuvant chemotherapy of cervical cancer has drawn more and more attention. Neoadjuvant chemotherapy can reduce the volume of lumps and eliminate subclinical metastasis in order to prolong the survival of patients. Many studies have shown that the intrinsic antigen components of cancer cells, genes and proteins are related to the sensitivity of chemotherapy. The detection of the relevant markers in patients before and after neoadjuvant chemotherapy to determine the patient’s efficacy, for patients with cervical cancer to make a comprehensive treatment program Provide evidence.